Our data demonstrates that baseline expression of CD163, a myeloid cell marker that can be used to estimate myeloid burden in tissue, is expressed at a similar level in tumor tissue at the time of resection in survivors and non-survivors. The gene discussed is CD163; the disease is neoplasm.